Increased cancer risks in myotonic dystrophy

Aung Ko Win, Promilla G. Perattur, Jose S Pulido, Christine M. Pulido, Noralane Morey Lindor

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: To estimate cancer risks for patients with myotonic dystrophy, given that increased risks for neoplasms in association with myotonic dystrophy type 1 and type 2 have been suggested in several studies but the risks of cancers have not been quantified. Patients and Methods: A cohort of 307 patients with myotonic dystrophy identified from medical records of Mayo Clinic in Rochester, MN, from January 1, l993, through May 28, 2010, was retrospectively analyzed. We estimated standardized incidence ratios (SIRs) of specific cancers for patients with myotonic dystrophy compared with age- and sex-specific cancer incidences of the general population. Age-dependent cumulative risks were calculated using the Kaplan-Meier method. Results: A total of 53 cancers were observed at a median age at diagnosis of 55 years. Patients with myotonic dystrophy had an increased risk of thyroid cancer (SIR, 5.54; 95% confidence interval [CI], 1.80-12.93; P=.001) and choroidal melanoma (SIR, 27.54; 95% CI, 3.34-99.49; P<.001). They may also have an increased risk of testicular cancer (SIR, 5.09; 95% CI, 0.62-18.38; P=.06) and prostate cancer (SIR, 2.21; 95% CI, 0.95-4.35; P=.05). The estimated cumulative risks at age 50 years were 1.72% (95% CI, 0.64%-4.55%) for thyroid cancer and 1.00% (95% CI, 0.25%-3.92%) for choroidal melanoma. There was no statistical evidence of an increased risk of brain, breast, colorectal, lung, renal, bladder, endometrial, or ovarian cancer; lymphoma; leukemia; or multiple myeloma. Conclusion: Patients with myotonic dystrophy may have an increased risk of thyroid cancer and choroidal melanoma and, possibly, testicular and prostate cancers.

Original languageEnglish (US)
Pages (from-to)130-135
Number of pages6
JournalMayo Clinic Proceedings
Volume87
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Myotonic Dystrophy
Confidence Intervals
Neoplasms
Incidence
Thyroid Neoplasms
Melanoma
Testicular Neoplasms
Prostatic Neoplasms
Endometrial Neoplasms
Multiple Myeloma
Urinary Bladder Neoplasms
Ovarian Neoplasms
Medical Records
Lymphoma
Leukemia
Breast
Kidney
Lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increased cancer risks in myotonic dystrophy. / Win, Aung Ko; Perattur, Promilla G.; Pulido, Jose S; Pulido, Christine M.; Lindor, Noralane Morey.

In: Mayo Clinic Proceedings, Vol. 87, No. 2, 02.2012, p. 130-135.

Research output: Contribution to journalArticle

Win, Aung Ko ; Perattur, Promilla G. ; Pulido, Jose S ; Pulido, Christine M. ; Lindor, Noralane Morey. / Increased cancer risks in myotonic dystrophy. In: Mayo Clinic Proceedings. 2012 ; Vol. 87, No. 2. pp. 130-135.
@article{7c1ff51f35734a82aebaa59c928028ca,
title = "Increased cancer risks in myotonic dystrophy",
abstract = "Objective: To estimate cancer risks for patients with myotonic dystrophy, given that increased risks for neoplasms in association with myotonic dystrophy type 1 and type 2 have been suggested in several studies but the risks of cancers have not been quantified. Patients and Methods: A cohort of 307 patients with myotonic dystrophy identified from medical records of Mayo Clinic in Rochester, MN, from January 1, l993, through May 28, 2010, was retrospectively analyzed. We estimated standardized incidence ratios (SIRs) of specific cancers for patients with myotonic dystrophy compared with age- and sex-specific cancer incidences of the general population. Age-dependent cumulative risks were calculated using the Kaplan-Meier method. Results: A total of 53 cancers were observed at a median age at diagnosis of 55 years. Patients with myotonic dystrophy had an increased risk of thyroid cancer (SIR, 5.54; 95{\%} confidence interval [CI], 1.80-12.93; P=.001) and choroidal melanoma (SIR, 27.54; 95{\%} CI, 3.34-99.49; P<.001). They may also have an increased risk of testicular cancer (SIR, 5.09; 95{\%} CI, 0.62-18.38; P=.06) and prostate cancer (SIR, 2.21; 95{\%} CI, 0.95-4.35; P=.05). The estimated cumulative risks at age 50 years were 1.72{\%} (95{\%} CI, 0.64{\%}-4.55{\%}) for thyroid cancer and 1.00{\%} (95{\%} CI, 0.25{\%}-3.92{\%}) for choroidal melanoma. There was no statistical evidence of an increased risk of brain, breast, colorectal, lung, renal, bladder, endometrial, or ovarian cancer; lymphoma; leukemia; or multiple myeloma. Conclusion: Patients with myotonic dystrophy may have an increased risk of thyroid cancer and choroidal melanoma and, possibly, testicular and prostate cancers.",
author = "Win, {Aung Ko} and Perattur, {Promilla G.} and Pulido, {Jose S} and Pulido, {Christine M.} and Lindor, {Noralane Morey}",
year = "2012",
month = "2",
doi = "10.1016/j.mayocp.2011.09.005",
language = "English (US)",
volume = "87",
pages = "130--135",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Increased cancer risks in myotonic dystrophy

AU - Win, Aung Ko

AU - Perattur, Promilla G.

AU - Pulido, Jose S

AU - Pulido, Christine M.

AU - Lindor, Noralane Morey

PY - 2012/2

Y1 - 2012/2

N2 - Objective: To estimate cancer risks for patients with myotonic dystrophy, given that increased risks for neoplasms in association with myotonic dystrophy type 1 and type 2 have been suggested in several studies but the risks of cancers have not been quantified. Patients and Methods: A cohort of 307 patients with myotonic dystrophy identified from medical records of Mayo Clinic in Rochester, MN, from January 1, l993, through May 28, 2010, was retrospectively analyzed. We estimated standardized incidence ratios (SIRs) of specific cancers for patients with myotonic dystrophy compared with age- and sex-specific cancer incidences of the general population. Age-dependent cumulative risks were calculated using the Kaplan-Meier method. Results: A total of 53 cancers were observed at a median age at diagnosis of 55 years. Patients with myotonic dystrophy had an increased risk of thyroid cancer (SIR, 5.54; 95% confidence interval [CI], 1.80-12.93; P=.001) and choroidal melanoma (SIR, 27.54; 95% CI, 3.34-99.49; P<.001). They may also have an increased risk of testicular cancer (SIR, 5.09; 95% CI, 0.62-18.38; P=.06) and prostate cancer (SIR, 2.21; 95% CI, 0.95-4.35; P=.05). The estimated cumulative risks at age 50 years were 1.72% (95% CI, 0.64%-4.55%) for thyroid cancer and 1.00% (95% CI, 0.25%-3.92%) for choroidal melanoma. There was no statistical evidence of an increased risk of brain, breast, colorectal, lung, renal, bladder, endometrial, or ovarian cancer; lymphoma; leukemia; or multiple myeloma. Conclusion: Patients with myotonic dystrophy may have an increased risk of thyroid cancer and choroidal melanoma and, possibly, testicular and prostate cancers.

AB - Objective: To estimate cancer risks for patients with myotonic dystrophy, given that increased risks for neoplasms in association with myotonic dystrophy type 1 and type 2 have been suggested in several studies but the risks of cancers have not been quantified. Patients and Methods: A cohort of 307 patients with myotonic dystrophy identified from medical records of Mayo Clinic in Rochester, MN, from January 1, l993, through May 28, 2010, was retrospectively analyzed. We estimated standardized incidence ratios (SIRs) of specific cancers for patients with myotonic dystrophy compared with age- and sex-specific cancer incidences of the general population. Age-dependent cumulative risks were calculated using the Kaplan-Meier method. Results: A total of 53 cancers were observed at a median age at diagnosis of 55 years. Patients with myotonic dystrophy had an increased risk of thyroid cancer (SIR, 5.54; 95% confidence interval [CI], 1.80-12.93; P=.001) and choroidal melanoma (SIR, 27.54; 95% CI, 3.34-99.49; P<.001). They may also have an increased risk of testicular cancer (SIR, 5.09; 95% CI, 0.62-18.38; P=.06) and prostate cancer (SIR, 2.21; 95% CI, 0.95-4.35; P=.05). The estimated cumulative risks at age 50 years were 1.72% (95% CI, 0.64%-4.55%) for thyroid cancer and 1.00% (95% CI, 0.25%-3.92%) for choroidal melanoma. There was no statistical evidence of an increased risk of brain, breast, colorectal, lung, renal, bladder, endometrial, or ovarian cancer; lymphoma; leukemia; or multiple myeloma. Conclusion: Patients with myotonic dystrophy may have an increased risk of thyroid cancer and choroidal melanoma and, possibly, testicular and prostate cancers.

UR - http://www.scopus.com/inward/record.url?scp=84856632995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856632995&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2011.09.005

DO - 10.1016/j.mayocp.2011.09.005

M3 - Article

C2 - 22237010

AN - SCOPUS:84856632995

VL - 87

SP - 130

EP - 135

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -